OMF Canada Triple Giving November logo

 TRIPLE YOUR IMPACT during Triple Giving November | All Donations to OMFCA are TRIPLED through December 2

Extended Big Data Study in Families

  • This project found:
    • Th2‑skewed cytokine activity is prominent and associates with cognitive impairment and sensory intolerance. Mast cell and eosinophil synergy may be a driver of the Th2 bias.
    • CCL11 is a potential biomarker for cognitive impairment.
    • BCL6 and TP53 emerge as candidate regulatory nodes potentially influencing immune set‑points and responses to medications/supplements.
  • The patient‑centered digital tools developed as part of this project (ME‑CFSTrackerApp, LexiTime) and the revamped severity assessment platform enable high‑resolution, real‑time phenotyping and response tracking.
  • Future work will focus on targeted validation of the signatures found in this project and evolving the digital tools.

STUDY HYPOTHESIS AND DESCRIPTION

In 2016, Fereshteh Jahanbani collaborated with Ron Davis and Mike Snyder to launch a study with the aim of deepening our understanding of how genetic and epigenetic variations impact our health, including our susceptibility to complex diseases such as ME/CFS and related comorbidities and multimorbidities.

The study was designed with the rationale that using unaffected family members as a control group would enable researchers to identify genetic and environmental risk factors that are associated with disease development, while longitudinal multi omics profiling could help to identify biomarkers and therapeutic strategies.

 OBJECTIVES